Kinetics of Microbial Translocation Markers in Patients on Efavirenz or Lopinavir/r Based Antiretroviral Therapy

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Vesterbacka, Jan ^a   Nowak, Piotr ^a   Barqasho, Babilonia ^a   Abdurahman, Samir ^a   Nyström, Jessica ^a   Nilsson, Staffan ^b   Funaoka, Hiroyuki ^c   Kanda, Tatsuo ^d   Andersson, Lars Magnus ^e   Gisslèn, Magnus ^e   Sönnerborg, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c DS Pharma Biomedical Co Ltd   (Japan)

^d NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ATAZANAVIR; CD146 ANTIGEN; COTRIMOXAZOLE; EFAVIRENZ; FATTY ACID BINDING PROTEIN 2; FLAGELLIN ANTIBODY; FLUCONAZOLE; LIPOPOLYSACCHARIDE; LOPINAVIR PLUS RITONAVIR; NITROFURANTOIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; SOLUBLE CD146 ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CARBOHYDRATE ANALYSIS; CD4 LYMPHOCYTE COUNT; CELL DAMAGE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTESTINE CELL; MAJOR CLINICAL STUDY; MALE; MICROBIAL TRANSLOCATION; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; PHASE 4 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTIBODIES, BACTERIAL; ANTIGENS, CD14; BACTERIA; BENZOXAZINES; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; DRUG COMBINATIONS; FATTY ACID-BINDING PROTEINS; FEMALE; FLAGELLIN; HIV-1; HUMANS; KINETICS; LIPOPOLYSACCHARIDES; LOPINAVIR; MALE; MIDDLE AGED; MOVEMENT; SOLUBILITY; TIME FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84873813972     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055038     Document Type: Article

References (46)

1. Shen L, Siliciano RF, (2008) Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 122: 22-28.
2. Karlsson AC, Gaines H, Sallberg M, Lindback S, Sonnerborg A, (1999) Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patients. J Virol 73: 6191-6196.
3. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, et al. (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105: 3879-3884.
4. Lindkvist A, Eden A, Norstrom MM, Gonzalez VD, Nilsson S, et al. (2009) Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study. AIDS Res Ther 6: 15.
5. Troseid M, Nowak P, Nystrom J, Lindkvist A, Abdurahman S, et al. (2010) Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy. AIDS 24: 1733-1737.
6. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.
7. Martinez E, Larrousse M, Gatell JM, (2009) Cardiovascular disease and HIV infection: host, virus, or drugs? Curr Opin Infect Dis 22: 28-34.
8. Boccara F, (2008) Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS 22Suppl 3: S19-26.
9. Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, et al. (2007) Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 196: 1779-1783.
10. Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, et al. (2011) Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med 5: 171-186.
11. Abdurahman S, Barqasho B, Nowak P, Cuong DD, Amogne W,et al. (2011) Elevated Flagellin-specific Antibodies during HIV-1 Infection. Abstract CROI 2011.
12. Pelsers MM, Namiot Z, Kisielewski W, Namiot A, Januszkiewicz M, et al. (2003) Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin Biochem 36: 529-535.
13. Sandler NG, Wand H, Roque A, Law M, Nason MC, et al. (2011) Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203: 780-790.
14. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, et al. (2010) Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 202: 1553-1561.
15. Chege D, Sheth PM, Kain T, Kim CJ, Kovacs C, et al. (2011) Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS 25: 741-749.
16. Bonora S, Nicastri E, Calcagno A, Gonzalez de Requena D, D'Ettorre G, et al. (2009) Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol 81: 400-405.
17. Josephson F, Andersson MC, Flamholc L, Gisslen M, Hagberg L, et al. (2010) The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naive HIV-1 infected patients. Eur J Clin Pharmacol 66: 349-357.
18. Eden A, Andersson LM, Andersson O, Flamholc L, Josephson F, et al. (2010) Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naive HIV-1-infected patients. AIDS Res Hum Retroviruses 26: 533-540.
19. Funaoka H, Kanda T, Kajiura S, Ohkaru Y, Fujii H, (2011) Development of a high-specificity sandwich ELISA system for the quantification of human intestinal fatty acid-binding protein (I-FABP) concentrations. Immunol Invest 40: 223-242.
20. Nowak P, Abdurahman S, Lindkvist A, Troseid M, Sonnerborg A, (2012) Impact of HMGB1/TLR Ligand Complexes on HIV-1 Replication: Possible Role for Flagellin during HIV-1 Infection. Int J Microbiol 2012: 263836.
21. Mizel SB, Bates JT, (2010) Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 185: 5677-5682.
22. Cassol E, Malfeld S, Mahasha P, van der Merwe S, Cassol S, et al. (2010) Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis 202: 723-733.
23. Wallet MA, Rodriguez CA, Yin L, Saporta S, Chinratanapisit S, et al. (2010) Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 24: 1281-1290.
24. Merlini E, Bai F, Bellistri GM, Tincati C, d'Arminio Monforte A, et al. (2011) Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One 6: e18580.
25. Marchetti G, Merlini E, Sinigaglia E, Iannotti N, Bai F,et al. (2012) Immune Reconstitution in HIV+ Subjects on Lopinavir/Ritonavir-Based HAART According to the Severity of Pre-Therapy CD4+. Curr HIV Res.
26. Rajasuriar R, Booth D, Solomon A, Chua K, Spelman T, et al. (2010) Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor alpha and microbial translocation. J Infect Dis 202: 1254-1264.
27. Marchetti G, Cozzi-Lepri A, Merlini E, Bellistri GM, Castagna A, et al. (2011) Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS 25: 1385-1394.
28. Douek DC, Roederer M, Koup RA, (2009) Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 60: 471-484.
29. Anas A, van der Poll T, de Vos AF, (2010) Role of CD14 in lung inflammation and infection. Crit Care 14: 209.
30. Ayaslioglu E, Kalpaklioglu F, Kavut AB, Erturk A, Capan N,et al. (2012) The role of CD14 gene promoter polymorphism in tuberculosis susceptibility. J Microbiol Immunol Infect.
31. Kanda T, Tsukahara A, Ueki K, Sakai Y, Tani T, et al. (2011) Diagnosis of ischemic small bowel disease by measurement of serum intestinal fatty acid-binding protein in patients with acute abdomen: a multicenter, observer-blinded validation study. J Gastroenterol 46: 492-500.
32. Palmisano L, Giuliano M, Nicastri E, Pirillo MF, Andreotti M, et al. (2005) Residual viraemia in subjects with chronic HIV infection and viral load <50 copies/ml: the impact of highly active antiretroviral therapy. AIDS 19: 1843-1847.
33. Nicastri E, Palmisano L, Sarmati L, D'Ettorre G, Parisi S, et al. (2008) HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens. Curr HIV Res 6: 261-266.
34. Derikx JP, Vreugdenhil AC, Van den Neucker AM, Grootjans J, van Bijnen AA, et al. (2009) A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP. J Clin Gastroenterol 43: 727-733.
35. Wiercinska-Drapalo A, Jaroszewicz J, Siwak E, Pogorzelska J, Prokopowicz D, (2008) Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis. Regul Pept 147: 25-28.
36. Pilon AA, Lum JJ, Sanchez-Dardon J, Phenix BN, Douglas R, et al. (2002) Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor. Antimicrob Agents Chemother 46: 2687-2691.
37. Blas-Garcia A, Esplugues JV, Apostolova N, (2011) Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicity. Curr Med Chem 18: 2186-2195.
38. Rizza SA, Badley AD, (2008) HIV protease inhibitors impact on apoptosis. Med Chem 4: 75-79.
39. Badley AD, (2005) In vitro and in vivo effects of HIV protease inhibitors on apoptosis. Cell Death Differ 12Suppl 1: 924-931.
40. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, et al. (2004) Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 113: 1296-1306.
41. Lien E, Aukrust P, Sundan A, Muller F, Froland SS, et al. (1998) Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood 92: 2084-2092.
42. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, et al. (2010) Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One 5: e9836.
43. Jernberg C, Lofmark S, Edlund C, Jansson JK, (2010) Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 156: 3216-3223.
44. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, et al. (2004) Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 364: 1428-1434.
45. Campbell JH, Burdo TH, Autissier P, Bombardier JP, Westmoreland SV, et al. (2011) Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV neuroAIDS. PLoS One 6: e18688.
46. Kalambokis GN, Tsianos EV, (2012) Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology 55: 655-656.